Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Acne Scarring of the Face
Interventions
BIOLOGICAL

Autologous Human Fibroblasts (azficel-T)

"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."

BIOLOGICAL

Placebo

"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."

Trial Locations (7)

10021

Sadick Dermatology, New York

21030

Maryland Laser, Skin and Vein Institute, Hunt Valley

28207

Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte

33146

Dermatology Research Institute, LLC, Coral Gables

90210

Brighton Medical Corporation, Beverly Hills

90404

The Laser Institute for Dermatology, Santa Monica

92123

Therapeutics Clinical Research, San Diego

Sponsors
All Listed Sponsors
lead

Castle Creek Biosciences, LLC.

INDUSTRY